Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta‑analysis of randomized controlled trials

Hu,Feng‑Huan; Yi,Xin; Yang,Yue‑Jing; Qiao,Shu‑Bin; Wu,Yong‑Jian; Yuan,Jian‑Song

doi:10.3892/etm.2013.1190

Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta‑analysis of randomized controlled trials

Authors:
- Feng‑Huan Hu
- Xin Yi
- Yue‑Jing Yang
- Shu‑Bin Qiao
- Yong‑Jian Wu
- Jian‑Song Yuan
View Affiliations

Affiliations: State Key Laboratory of Cardiovascular Disease, Coronary Artery Diseases Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, P.R. China, Department of Cardiovascular Medicine, Beijing Hui People Hospital, Beijing 100054, P.R. China
Published online on: July 1, 2013 https://doi.org/10.3892/etm.2013.1190
Pages: 819-825

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have shown that the combination of cilostazol and aspirin may be a more effective regimen than ticlopidine plus aspirin in the prevention of late restenosis and acute or subacute stent thrombosis following coronary stenting; however, individually published results are inconclusive. The aim of this meta‑analysis was to compare the differences in late restenosis and stent thrombosis between cilostazol plus aspirin and ticlopidine plus aspirin for patients with coronary heart disease (CHD) following coronary stenting. A literature search of Pubmed, Embase, Web of Science and Chinese BioMedicine (CBM) databases was conducted from 1998 to March 1, 2013 and statistical analysis was performed using Stata statistical software, version 12.0. Twelve randomized controlled trials were included in the study, with a total of 2,708 patients with CHD following coronary stenting. The patient population comprised 1,371 patients treated with cilostazol plus aspirin and 1,337 patients treated with ticlopidine plus aspirin. The meta‑analysis showed that cilostazol plus aspirin demonstrated a lower rate of restenosis than ticlopidine plus aspirin [odds ratio (OR)=0.83, 95% confidence interval (CI)=0.69‑0.99, P=0.047]. A significant difference was also observed in the average percent diameter stenosis between cilostazol plus aspirin and ticlopidine plus aspirin [standardized weight difference (SMD)=‑0.57, 95% CI=‑0.92, ‑0.23, P=0.001). However, there were no significant differences in the rates of acute or subacute stent thrombosis between cilostazol plus aspirin and ticlopidine plus aspirin. The present meta‑analysis suggests that cilostazol plus aspirin may result in a lower restenosis rate and percent diameter stenosis than ticlopidine plus aspirin for patients with CHD following coronary stenting.

View Figures

View References

1	Fatima S, Ahmad SI and Ahmad HR: The intercept and slope of breathlessness/chest pain-heart rate relationship in patients with coronary artery disease using exercise tolerance test. J Pak Med Assoc. 62:382–385. 2012.PubMed/NCBI
2	Kang YH, Lao HY, Yu XY, Chen JY and Zhong SL: Progress in genetic and epigenetic research on in-stent restenosis after percutaneous coronary interventions. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 29:38–42. 2012.(In Chinese).
3	Ge J, Han Y, Jiang H, et al; RACTS (Randomized Prospective Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting) Trial Investigators. RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. J Cardiovasc Pharmacol. 46:162–166. 2005. View Article : Google Scholar
4	Han Y, Wang S, Li Y, et al: Cilostazol improves long-term outcomes after coronary stent implantation. Am Heart J. 150:5682005.PubMed/NCBI
5	Nagaoka N, Matsubara T, Okazaki K, Masuda N, Shikaura K and Hotta A: Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J. 42:43–54. 2001. View Article : Google Scholar : PubMed/NCBI
6	Hashiguchi M, Ohno K, Nakazawa R, Kishino S, Mochizuki M and Shiga T: Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovasc Drugs Ther. 18:211–217. 2004. View Article : Google Scholar : PubMed/NCBI
7	Harding SA, Walters DL, Palacios IF and Oesterle SN: Adjunctive pharmacotherapy for coronary stenting. Curr Opin Cardiol. 16:293–299. 2001. View Article : Google Scholar : PubMed/NCBI
8	Tanabe Y, Ito E, Nakagawa I and Suzuki K: Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol. 78:285–291. 2001. View Article : Google Scholar : PubMed/NCBI
9	Jang JS, Jin HY, Seo JS, et al: A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology. 122:133–143. 2012. View Article : Google Scholar : PubMed/NCBI
10	Nakamura T, Tsuruta S and Uchiyama S: Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. J Neurol Sci. 313:22–26. 2012. View Article : Google Scholar
11	Dangas G, Mehran R, Abizaid AS, et al: Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am J Cardiol. 87:470–472. 2001. View Article : Google Scholar : PubMed/NCBI
12	Rogers KC, Faircloth JM and Finks SW: Use of cilostazol in percutaneous coronary interventions. Ann Pharmacother. 46:839–850. 2012. View Article : Google Scholar : PubMed/NCBI
13	Geng DF, Liu M, Jin DM, Wu W, Deng J and Wang JF: Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology. 122:148–157. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sekiguchi M, Hoshizaki H, Adachi H, Ohshima S, Taniguchi K and Kurabayashi M: Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol. Circ J. 68:610–614. 2004. View Article : Google Scholar : PubMed/NCBI
15	Maher CG, Sherrington C, Herbert RD, Moseley AM and Elkins M: Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther. 83:713–721. 2003.PubMed/NCBI
16	Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002. View Article : Google Scholar : PubMed/NCBI
17	Zintzaras E and Ioannidis JP: Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 28:123–137. 2005. View Article : Google Scholar : PubMed/NCBI
18	Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L: Comparison of two methods to detect publication bias in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
19	Hong B, Qian JY, Fan B, Jin XJ and Ge JB: A randomized trial of cilostazol versus ticlopidine for anti-platelet therapy after coronary artery stenting for prevention of restenosis. Chin J Intervent Cardiol. 14:170–172. 2006.(In Chinese).
20	Inoue T, Uchida T, Sakuma M, et al: Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol. 44:1408–1414. 2004. View Article : Google Scholar : PubMed/NCBI
21	Kamishirado H, Inoue T, Mizoguchi K, et al: Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J. 144:303–308. 2002. View Article : Google Scholar
22	Kozuma K, Hara K, Yamasaki M, et al: Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J. 141:124–130. 2001. View Article : Google Scholar : PubMed/NCBI
23	Park SW, Lee CW, Kim HS, et al: Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 86:499–503. 2000. View Article : Google Scholar : PubMed/NCBI
24	Takeyasu N, Watanabe S, Noguchi Y, Ishikawa K, Fumikura Y and Yamaguchi I: Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting. Circ J. 69:780–785. 2005. View Article : Google Scholar : PubMed/NCBI
25	Yoon Y, Shim WH, Lee DH, et al: Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol. 84:1375–1380. 1999. View Article : Google Scholar : PubMed/NCBI
26	Jennings DL and Kalus JS: Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol. 50:415–421. 2010. View Article : Google Scholar : PubMed/NCBI
27	Rubboli A, Milandri M, Castelvetri C and Cosmi B: Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology. 104:101–106. 2005. View Article : Google Scholar
28	Cosmi B, Rubboli A, Castelvetri C and Milandri M: Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev. CD0021332001.PubMed/NCBI
29	Schleinitz MD, Olkin I and Heidenreich PA: Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. Am Heart J. 148:990–997. 2004. View Article : Google Scholar : PubMed/NCBI